0001178913-22-001072.txt : 20220314 0001178913-22-001072.hdr.sgml : 20220314 20220314162011 ACCESSION NUMBER: 0001178913-22-001072 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220311 FILED AS OF DATE: 20220314 DATE AS OF CHANGE: 20220314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Darvish Nissim CENTRAL INDEX KEY: 0001793602 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 22736897 MAIL ADDRESS: STREET 1: C/O INNOVATE BIOPHARMACEUTICALS, INC. STREET 2: 8480 HONEYCUTT ROAD, SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 4 1 zk2227476.xml X0306 4 2022-03-11 0 0001534248 Chemomab Therapeutics Ltd. CMMB 0001793602 Darvish Nissim C/O CHEMOMAB THERAPEUTICS LTD. KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 ISRAEL 1 0 0 0 American Depositary Shares 2022-03-11 4 P 0 1200 4.28 A 1200 D Option to Purchase American Depositary Shares 3.53 2022-03-07 4 A 0 6820 0 A 2032-03-07 American Depositary Shares 6820 6820 D Option to Purchase American Depositary Shares 27.26 2021-04-19 4 A 0 11884 0 A 2031-04-19 American Depositary Shares 11884 11884 D Option to Purchase American Depositary Shares 0.8 2021-03-16 4 A 0 10123 0 A 2026-10-27 American Depositary Shares 10123 10123 D Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. The ADSs are held of record directly by the Ashdanit Medical Ltd. (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole ultimate beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. These options vest and become exercisable in their entirety on March 16, 2023, subject to the Reporting Person's continued service. These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service. /s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish 2022-03-14